Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

Hong Kong’s stock exchange could become a hub for mainland Chinese biotechnology firms thanks to a sweeping reform of listing rules, said the boss of BeiGene, the first such company to take advantage …
( read original story …)


Related Post

Hong Kong on track for global IPO crown
views 7
Hong Kong is on course to take the global IPO crow...
Hong Kong IPOs to raise HK$100 billion less in 201...
views 8
Seven companies listed in Hong Kong slashed their ...
China’s Tencent Music raises nearly $1.1 bil...
views 8
NEW YORK/HONG KONG (Reuters) - China-based music s...
WuXi AppTec Lists H Shares on the Hong Kong Stock ...
views 8
The Hong Kong IPO will be used to enhance the Comp...
Hong Kong: HANG SENG INDEX (.HSI) market participa...
views 8
Hong Kong stocks rose on Wednesday as market parti...
Hong Kong shelves ETF Connect scheme with China du...
views 8
It will need a very long period of discussion to e...
Investors are still optimistic about Hong Kong des...
views 13
The start-ups employed a total of 9,548 people, a ...
Annuities perked up after cool response
views 16
The Hong Kong Mortgage Corporation will introduce ...
Hong Kong: HANG SENG INDEX (.HSI) worries about a ...
views 17
Headline shares of the Hong Kong financial market ...
Hang Seng, Tencent join hands
views 18
... and Hang Seng will further promote fintech dev...